Evidence map›Paper›PMID 37817214›Full record

ArticleDiabetology & metabolic syndrome2023

Effects of COVID-19 on diabetes care among dutch diabetes outpatients.

Jessica C G Bak, Erik H Serné, Rolf H H Groenwold, Harold W de Valk, Mark H H Kramer, Max Nieuwdorp, Carianne L Verheugt

Open access · goldAbstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jessica C G BakDepartment of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Erik H SernéDepartment of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Rolf H H GroenwoldLeiden University Medical Center, Leiden, the Netherlands.
Harold W de ValkUniversity Medical Center Utrecht, Utrecht, the Netherlands.
Mark H H KramerDepartment of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Max NieuwdorpDepartment of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Carianne L VerheugtDepartment of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands. c.verheugt@amsterdamumc.nl.
Amsterdam University Medical Centers · NLDutch Institute for Clinical Auditing · NLLeiden University Medical Center · NLUniversity Medical Center Utrecht · NL

Funding

ZonMw [09150182010020]
6 · The paper itself

Abstract

aimsThe COVID-19 pandemic impacted diabetes care by reducing diabetes outpatient visits and diabetes-related screening due to allocation of healthcare resources. Yet the impact of COVID-19 on diabetes outpatients has not been extensively evaluated. This study aimed to assess the effect of the COVID-19 pandemic on diagnostics and intermediate outcomes of outpatient diabetes care pre- and during COVID.

methodsThis observational cohort study included 8,442 diabetes patients in the Dutch Pediatric and Adult Registry of Diabetes (DPARD) visiting diabetes outpatient clinics in 2019 and 2021. A mixed-effects regression analysis was used to examine differences in target achievement of HbA1c, BMI, blood pressure, LDL-cholesterol, eGFR, and the difference in mean HbA1c between 2019 and 2020 among n = 1,426 outpatients who visited in both years. Analyses were adjusted for age, sex, and BMI.

resultsA 22.7% (21.6-23.8%, p < 0.001) decline in outpatient volume was observed during the pandemic (2020). BMI, lipid spectrum, kidney function, and HbA1c were assessed less frequently in 2020 than in 2019. In 2020, compared to 2019, the median HbA1c level increased by 2.2% (1.0 mmol/mol, p = 0.035) and the percentages of patients with known HbA1C meeting targets below 10, 8, 7% (86, 64, and 53 mmol/mol) decreased by 0.5%, 1.7% and 1.4%, respectively. Target blood pressure ≤ 130/80 mmHg was achieved more often in 2020 (15.0% versus 18.3%, p = 0.018), while HbA1c ≤ 86 mmol/mol was achieved less (89.3% versus 87.1%, p = 0.001), among diabetes outpatients seen in both 2019 and 2020. In patients visiting both years, HbA1c was 2.3% (1.9 mmol/l, 95% CI 1.2-2.5, p < 0.001) lower during the pandemic than in the prepandemic (2019).

conclusionsThe COVID pandemic was associated with a marked reduction in patient volume in diabetes outpatient care among five hospitals. Among patients who received outpatient care both before and during the pandemic period, HbA1c control and blood pressure control enhanced during the pandemic. Re-evaluation of current diabetes outpatient care organization is warranted to ensure optimal diabetes care in future times.

Indexed as

COVID-19Diabetes careOutpatientsPandemic

Identifiers

PMID37817214
PMCPMC10563332
OpenAlexW4387501104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.